PT - JOURNAL ARTICLE AU - Lucas A Salas AU - Sara N. Lundgren AU - Eva P. Browne AU - Elizabeth C. Punska AU - Douglas L. Anderton AU - Margaret R Karagas AU - Kathleen F. Arcaro AU - Brock C. Christensen TI - Prediagnostic breast milk DNA methylation alterations in women who develop breast cancer AID - 10.1101/19001925 DP - 2019 Jan 01 TA - medRxiv PG - 19001925 4099 - http://medrxiv.org/content/early/2019/07/12/19001925.short 4100 - http://medrxiv.org/content/early/2019/07/12/19001925.full AB - Background Prior candidate gene studies have shown tumor suppressor DNA methylation in breast milk related with history of breast biopsy, an established risk factor for breast cancer. To further establish the utility of breast milk as a tissue-specific biospecimen for investigations of breast carcinogenesis we measured genome-wide DNA methylation in breast milk from women with and without a diagnosis of breast cancer in two independent cohorts.Methods DNA methylation was assessed using Illumina HumanMethylation450k in 87 breast milk samples. After quality control, 368,171 autosomal CpG loci were analyzed. Cell type proportion estimates from RefFreeCellMix were calculated and adjusted for in this Epigenome Wide Association Study using linear mixed effects models adjusted for history of breast biopsy, age, time of delivery, cell type proportion estimates, array chip, and subject as random effect.Results Epigenome-wide analyses identified 58 differentially methylated CpG sites associated with a breast cancer diagnosis in the prospectively collected milk samples from the breast that would develop cancer compared with women without a diagnosis of breast cancer (q-value < 0.05). Nearly all CpG sites associated with a breast cancer diagnosis were hypomethylated in cases compared with controls, and were enriched for CpG islands. In addition, inferred repeat element methylation was lower in breast milk DNA from cases compared to controls, and cases exhibited increased estimated epigenetic mitotic tick rate as well as DNA methylation age compared with controls.Conclusion Breast milk has utility as a biospecimen for prospective assessment of disease risk, for understanding the underlying molecular basis of breast cancer risk factors, and improving primary and secondary prevention of breast cancer.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by funds of the COBRE Center for Molecular Epidemiology at Dartmouth P20GM104416, and R01CA216265 to BCC; NIEHS P01ES022832 and EPA RD83544201 to MRK; and R01CA230478-01A1 to KFAAuthor DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.Not ApplicableThe datasets generated and analyzed during the current study are available in the GEO (https://www.ncbi.nlm.nih.gov/geo/) under the accession number GSE133918.EWASEpigenome-wide association studiesepiTOCepigenetic mitotic clock tick rateMSigDBmolecular signatures databaseUMassUniversity of Massachusetts AmherstNHBCSNew Hampshire Birth Cohort studymAgemethylation age